A1GI34.SA Agilent Technologies Inc.
- Market cap
- BRL 274B
- P/E
- 36.4x
- P/B
- 6.88x
- ROE
- 18.2%
- Dividend yield
- 0.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is A1GI34.SA undervalued?
Graham numberThe Graham number of Agilent Technologies Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Agilent Technologies Inc. fundamental analysis
No fundamental analysis for Agilent Technologies Inc. yet.
Agilent Technologies Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract dev…
Full company profileAgilent Technologies Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Agilent Technologies Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 5.16B | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | 6.95B | 7.35B |
| Gross Profit | 2.81B | 2.84B | 3.41B | 3.72B | 3.48B | 3.55B | 3.66B | 3.98B |
| Operating Income | 941M | 846M | 1.35B | 1.62B | 1.39B | 1.49B | 1.49B | 1.59B |
| EBITDA | 1.23B | 1.23B | 1.76B | 1.91B | 1.71B | 1.87B | 1.84B | 1.99B |
| Net Income | 1.07B | 719M | 1.21B | 1.25B | 1.24B | 1.29B | 1.30B | 1.34B |
| EPS | 3.47 | 2.35 | 4.01 | 4.25 | 4.24 | 4.52 | 4.60 | 4.76 |
| Balance Sheet | ||||||||
| Total Assets | 9.45B | 9.63B | 10.7B | 10.5B | 10.8B | 11.8B | 12.7B | 14.0B |
| Total Liabilities | 4.70B | 4.75B | 5.32B | 5.23B | 4.92B | 5.95B | 5.99B | 6.60B |
| Shareholders' Equity | 4.75B | 4.87B | 5.39B | 5.29B | 5.85B | 5.90B | 6.74B | 7.36B |
| Cash & Short-term Investments | 1.38B | 1.44B | 1.58B | 1.05B | 1.59B | 1.33B | 1.79B | 1.76B |
| Cash Flow | ||||||||
| Operating Cash Flow | 1.02B | 921M | 1.49B | 1.31B | 1.77B | 1.75B | 1.56B | 1.42B |
| Capital Expenditure | 155M | 119M | 188M | 291M | 298M | 378M | 407M | 332M |
| Free Cash Flow | 865M | 802M | 1.30B | 1.02B | 1.47B | 1.37B | 1.15B | 1.09B |
| Ratios | ||||||||
| ROE | 22.6% | 14.8% | 22.5% | 23.7% | 21.2% | 21.9% | 19.3% | 18.2% |
| ROA | 11.3% | 7.5% | 11.3% | 11.9% | 11.5% | 10.9% | 10.2% | 9.6% |
| Net Profit Margin | 20.7% | 13.5% | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% | 18.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Agilent Technologies Inc. dividends
- Dividend yield
- 0.39%
- Forward dividend
- 0.38 BRL
- Payout ratio
- 21.6%
- Ex-dividend date
- Oct 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 282M | 1.00 | 21.6% |
| 2024 | USD 274M | 0.96 | 21.3% |
| 2023 | USD 265M | 0.91 | 21.4% |
| 2022 | USD 250M | 0.85 | 19.9% |
| 2021 | USD 236M | 0.78 | 19.5% |
| 2020 | BRL 222M | 0.73 | 30.9% |
| 2019 | BRL 206M | 0.67 | 19.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Aug 10, 2026.
Who owns Agilent Technologies Inc.
Ownership data of Agilent Technologies Inc. is not available yet.
Agilent Technologies Inc. company profile
- Company name
- Agilent Technologies Inc.
- Ticker
- A1GI34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18,200
- Fiscal year end
- October
- Address
- 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051
- Phone
- 800 227 9770
- Website
- agilent.com
About Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Agilent Technologies Inc. management
10- Mr. Padraig McDonnellCEO, President & Director · born 1972
- Mr. Rodney GonsalvesVice President of Finance · born 1966
- Ms. Angelica A. RiemannSenior VP & President of Agilent CrossLab Group · born 1971
- Dr. Simon MaySenior VP and President of Life Sciences & Diagnostics Markets Group · born 1973
- Mr. Bret M. DiMarcoSpecial Advisor · born 1968
- Mr. Adam S. ElinoffSenior VP, CFO & Principal Financial Officer · born 1978
- Mr. Tim DownsVP & Chief Accounting Officer · born 1981
- Mr. August Specht Ph.D.Senior VP & Chief Technology Officer
- Mr. Tejas Rajeev SavantVice President of Investor Relations
- Mr. Michael BucknerSenior VP, Chief Legal Officer & Secretary